5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate that was approved in 2011 for the treatment of patients with anaplastic large cell and Hodgkin lymphomas. The product label indicates that 3 patients who were treated with BV developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC virus-induced central nervous system infection. Prior immunosuppressive therapy and compromised immune systems were postulated risk factors. In the current study, the authors reported 5 patients who developed BV-associated PML, including 2 immunocompetent patients.

          Related collections

          Author and article information

          Journal
          Cancer
          Cancer
          1097-0142
          0008-543X
          Aug 15 2014
          : 120
          : 16
          Affiliations
          [1 ] Division of Medical Oncology, Washington University School of Medicine, St Louis, Missouri.
          Article
          NIHMS602748
          10.1002/cncr.28712
          24771533
          88302430-b03e-425e-bf1b-fbba365e85e7
          © 2014 American Cancer Society.
          History

          autoimmune,brentuximab,fungoides,immunocompromised,lymphoma,vedotin

          Comments

          Comment on this article